Fej-nyaki daganatok: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 70
• PD-L1 42
• TP53 7
• EGFR 33
• PI3K 6
• STAT3 1
• BRAF 0
• AKT 2
• mTOR 0
• HER2 6
• RET 0
• MAPK 0
• ERK 0
• STING 0
• PTEN 1
• TERT 0
• CTNNB1 0
• JAK 1
• CTLA-4 4
• NRF2 0
• MYC 0
• VEGF 4
• YAP 1
• HIF-1 0
• MET 3
• AMPK 0
• CLDN18 0
• IL-6 2
• JNK 0
• PARP 1
• FGFR 1
• GPX4 0
• B7-H3 5
• CD47 1
• COX-2 0
• LAG-3 2
• TROP2 5
• EZH2 0
• MEK 0
• METTL3 0
• PIK3CA 4
• CDK4/6 2
• NLRP3 0
• ATM 0
• PKM2 0
• TNF 0
• FAK 0
• MMP-9 0
• PPAR 0
• PSMA 1
• TLR4 0
• BCL-2 0
• HSP90 0
• KRAS 0
• NOTCH1 0
• NTRK 1
• ALK 0
• CD40 1
• CDKN2A 2
• CXCR4 0

1127 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIDCR · F31

  Investigating the impact of radiation therapy on oral squamous cell carcinoma microenvironment via non-classical class I major histocompatibility complex HLA-E

  University of California at Davis· Davis, Egyesült Államok· 43 748 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NIDCR · F32

  Transposon derived neo-antigens in NSD1 mutant Head and Neck Cancers

  Columbia University Health Sciences· New York, Egyesült Államok· 77 580 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, Egyesült Államok· 768 308 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NIDCR · R01

  Restoring responses to immunotherapy in metastatic lymph nodes in HNSCC

  University of California, San Francisco· San Francisco, Egyesült Államok· 684 832 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NIDCR · R01

  Advancing FTIR-based Multimodal Imaging with AI for Risk Stratification of Oral Precancer

  University of Missouri Kansas City· Kansas City, Egyesült Államok· 527 533 USD awarded in fiscal year 2026· until 2030. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetic Profiling and Telomere-Orchestrated Mechanisms in HPV+ Oropharyngeal Cancer (EPiTOME-M)

  Royal College of Surgeons in Ireland· Dublin 2, Írország· EU contribution 268 569 EUR· until 2028. nov.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Endoscopic tissue time machine (EPIC)

  King's College London· London, Egyesült Királyság· EU contribution 2 273 033 EUR· until 2031. máj.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  From Whisper to Voice: Real-Time on-Device Assistive AI Technology for Human Connection (Whispp)

  Whispp Bv· Leiden, Hollandia· EU contribution 2 498 319 EUR· until 2028. máj.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  INHIBITING RESISTANCE TO IMMUNOTHERAPY IN HEAD&NECK CANCER BY TARGETING NETRIN-1 (NeckNET)

  Netris Pharma Sas· Lyon, Franciaország· EU contribution 7 248 398 EUR· until 2030. máj.· 4 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  Early clinical development of first-in-class EGL-001 targeting Tregs in head and neck squamous cell carcinoma, supported by AI-based pathomics (NEOTREG)

  Egle Therapeutics· Suresnes, Franciaország· EU contribution 7 999 120 EUR· until 2028. nov.· 4 countries

10 of 635 running projects, newest first. Listed amounts together: 366,0 M USD + 36,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

  NCT05462873· Novartis Pharmaceuticals· Frissítve: 2026. nov. 13.

  “Business decision and not related to safety concerns”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

  NCT01810913· National Cancer Institute (NCI)· Frissítve: 2026. nov. 12.

  “Other - Assessing accrual feasibility”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer

  NCT04001543· Institut du Cancer de Montpellier - Val d'Aurelle· Frissítve: 2026. nov. 9.

  “A change in patient care. Competing trials with the expansion of immunotherapies, Difficulties in manufacturing and obtaining products for double-blind studies. The health situation, with an temporary halt due to COVID-19.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Frissítve: 2026. okt. 26.

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of E7130 in Participants With Solid Tumors

  NCT03444701· Eisai Co., Ltd.· Frissítve: 2026. okt. 23.

  “The trial was prematurely terminated due to the sponsor's decision.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Digital Phenotyping of Psychological Distress in Skin Cancer Patients

  NCT07670403· West China Hospital· Frissítve: 2026. okt. 16.

  “poor accrual”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

  NCT06741982· West China Hospital· Frissítve: 2026. okt. 16.

  “The study was withdrawn prior to participant enrollment due to administrative and protocol optimization considerations.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

  NCT06091930· Boehringer Ingelheim· Frissítve: 2026. okt. 14.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Compass Therapeutics· Frissítve: 2026. okt. 9.

  “The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

  NCT07513324· Dana-Farber Cancer Institute· Frissítve: 2026. okt. 8.

  “study halted prematurely prior to enrollment of first participant”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

  NCT02567422· National Cancer Institute (NCI)· Forrás

• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

  NCT07667400· National Cancer Institute (NCI)· Forrás

• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

  NCT04576091· National Cancer Institute (NCI)· Forrás

• Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

  NCT03803774· National Cancer Institute (NCI)· Forrás

• De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

  NCT03952585· National Cancer Institute (NCI)· Forrás

• Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer

  NCT07784855· West Virginia University· Forrás

• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

  NCT05063552· National Cancer Institute (NCI)· Forrás

• Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

  NCT03811015· National Cancer Institute (NCI)· Forrás

• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

  NCT05172258· National Cancer Institute (NCI)· Forrás

• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

  NCT04671667· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 84
• Organoids 23
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 13
• Gene Expression Profiling 244
• Sequence Analysis, RNA 26
• Whole Genome Sequencing 7
• Exome Sequencing 22
• Proteomics 65
• Metabolomics 43
• Mass Spectrometry 14
• Flow Cytometry 56
• Immunohistochemistry 333
• Liquid Biopsy 34
• Circulating Tumor DNA 57
• Xenograft Model Antitumor Assays 308
• Positron-Emission Tomography 83
• Magnetic Resonance Imaging 276
• Machine Learning 232
• Deep Learning 187
• Cohort Studies 296
• Genome-Wide Association Study 55

• Tumor microenvironment-simulated organoids for personalized therapy prediction in head and neck squamous cell carcinoma.

  Oncogene, 2026. aug.

• A novel chalcone analog inhibits cancer stemness in CD44+ and CD133+ populations via suppression of ERK signaling.

  Exp Cell Res, 2026. máj.

• Clinical Value of Patient-Derived Tumor Organoids in Guiding Precision Chemotherapy for Locally Advanced Thyroid Cancer: A Single-Center, Single-Arm, Phase 2 Trial.

  Int J Cancer, 2026. ápr.

• HERC1 oncogene enhances stemness and tumorigenic potential in CD44+-derived organoids of head and neck squamous cell carcinoma through IL-6/STAT3 signaling.

  Oncogene, 2026. ápr.

• Establishment of Tumor Organoids, Carcinoma-Associated Fibroblasts, and Counterpart Fibroblasts from the Same Esophageal Cancer Patient.

  J Vis Exp, 2026. ápr.

• SREBP1-mediated lipid metabolism reprogramming drives malignant progression and therapeutic resistance in HPSCC organoids and animal models.

  Biomater Sci, 2026. márc.

• Microfluidic-based patient-derived organoids recapitulate thyroid cancer heterogeneity and reveal NF-κB-driven maturation for precision therapy.

  J Transl Med, 2026. febr.

• Radiation-induced interferon-I response impairs thyroid organoid function.

  Radiother Oncol, 2026. febr.

• A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinoma.

  Cell Rep Med, 2026. febr.

• Organoid modeling identifies EDN1 as a potential oncogenic driver in papillary thyroid carcinoma via modulation of the Hippo-YAP signaling pathway.

  J Endocrinol Invest, 2026. jan.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.